TAMC-derived creatine sustains glioblastoma growth

Huiwen Yan; Pengcheng Bu

doi:10.1016/j.cmet.2023.12.012

TAMC-derived creatine sustains glioblastoma growth

Cell Metab. 2024 Jan 2;36(1):1-3. doi: 10.1016/j.cmet.2023.12.012.

Authors

Huiwen Yan¹, Pengcheng Bu²

Affiliations

¹ Key Laboratory of Epigenetic Regulation and Intervention, Chinese Academy of Sciences, Beijing 100101, China; Key Laboratory of RNA Biology, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.
² Key Laboratory of Epigenetic Regulation and Intervention, Chinese Academy of Sciences, Beijing 100101, China; Key Laboratory of RNA Biology, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China. Electronic address: bupc@ibp.ac.cn.

PMID: 38171329
DOI: 10.1016/j.cmet.2023.12.012

Abstract

Tumor-associated myeloid cells (TAMCs) are the predominant immune population in glioblastoma (GBM), but the definite role of TAMCs in GBM tumorigenicity remains uncertain. In this issue of Cell Metabolism, Rashidi et al. identify a specific population of TAMCs surrounding hypoxic regions of GBM. These TAMCs provide creatine to nearby tumor cells to promote GBM progression.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Brain Neoplasms* / metabolism
Brain Neoplasms* / pathology
Cell Line, Tumor
Creatine
Glioblastoma* / metabolism
Humans
Myeloid Cells / metabolism
Tumor Microenvironment

Substances

Creatine